Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
High-Grade Epstein-Barr Virus-Negative Biphenotypic Lymphoma with Expression of B- and T-Cell Markers and Leukemia Presentation: Case Report and Literature Review.

Case reports in oncology

Kohla S, Ibrahim FA, Mudawi D, Akiki S, Soliman D, Al-Sabbagh A, Youssef RRH, Yassin MA.
PMID: 33173488
Case Rep Oncol. 2020 Sep 30;13(3):1215-1226. doi: 10.1159/000510403. eCollection 2020.

Lymphomas are presently categorized according to their origin from B or T lymphocytes. The co-expression of CD3 in B-cell lymphomas or CD20 in T-cell lymphomas has been rarely reported. Immature and less often mature lymphomas may incorporate the rearrangements...

Cite
Kohla S, Ibrahim FA, Mudawi D, et al. High-Grade Epstein-Barr Virus-Negative Biphenotypic Lymphoma with Expression of B- and T-Cell Markers and Leukemia Presentation: Case Report and Literature Review. Case Rep Oncol. 2020;13(3):1215-1226doi: 10.1159/000510403.
Kohla, S., Ibrahim, F. A., Mudawi, D., Akiki, S., Soliman, D., Al-Sabbagh, A., Youssef, R. R. H., & Yassin, M. A. (2020). High-Grade Epstein-Barr Virus-Negative Biphenotypic Lymphoma with Expression of B- and T-Cell Markers and Leukemia Presentation: Case Report and Literature Review. Case reports in oncology, 13(3), 1215-1226. https://doi.org/10.1159/000510403
Kohla, Samah, et al. "High-Grade Epstein-Barr Virus-Negative Biphenotypic Lymphoma with Expression of B- and T-Cell Markers and Leukemia Presentation: Case Report and Literature Review." Case reports in oncology vol. 13,3 (2020): 1215-1226. doi: https://doi.org/10.1159/000510403
Kohla S, Ibrahim FA, Mudawi D, Akiki S, Soliman D, Al-Sabbagh A, Youssef RRH, Yassin MA. High-Grade Epstein-Barr Virus-Negative Biphenotypic Lymphoma with Expression of B- and T-Cell Markers and Leukemia Presentation: Case Report and Literature Review. Case Rep Oncol. 2020 Sep 30;13(3):1215-1226. doi: 10.1159/000510403. eCollection 2020. PMID: 33173488; PMCID: PMC7590753.
Copy Download .nbib Format: NLM
Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept.

Cancers

León-Triana O, Pérez-Martínez A, Ramírez-Orellana M, Pérez-García VM.
PMID: 33572301
Cancers (Basel). 2021 Feb 09;13(4). doi: 10.3390/cancers13040703.

Chimeric antigen receptor (CAR)-T cell-based therapies have achieved substantial success against B-cell malignancies, which has led to a growing scientific and clinical interest in extending their use to solid cancers. However, results for solid tumours have been limited up...

Cite
León-Triana O, Pérez-Martínez A, Ramírez-Orellana M, et al. Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept. Cancers (Basel). 2021;13(4)doi: 10.3390/cancers13040703.
León-Triana, O., Pérez-Martínez, A., Ramírez-Orellana, M., & Pérez-García, V. M. (2021). Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept. Cancers, 13(4), . https://doi.org/10.3390/cancers13040703
León-Triana, Odelaisy, et al. "Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept." Cancers vol. 13,4 (2021). doi: https://doi.org/10.3390/cancers13040703
León-Triana O, Pérez-Martínez A, Ramírez-Orellana M, Pérez-García VM. Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept. Cancers (Basel). 2021 Feb 09;13(4). doi: 10.3390/cancers13040703. PMID: 33572301; PMCID: PMC7916125.
Copy Download .nbib Format: NLM
IgM multiple myeloma presenting with bleeding tendency: a case report with immunophenotype analysis.

Oncology letters

Zheng L, Zeng Z, Lin J, Chen J.
PMID: 22870128
Oncol Lett. 2011 Jan;2(1):55-57. doi: 10.3892/ol.2010.216. Epub 2010 Nov 23.

IgM multiple myeloma (MM) is an extremely rare lymphoproliferative disease associated with an aggressive clinical course. However, the diagnosis of IgM MM may be complicated by Waldenstrom's macroglobulinemia (WM), particularly when clinical manifestations and morphological features are not typical....

Cite
Zheng L, Zeng Z, Lin J, et al. IgM multiple myeloma presenting with bleeding tendency: a case report with immunophenotype analysis. Oncol Lett. 2010;2(1):55-57doi: 10.3892/ol.2010.216.
Zheng, L., Zeng, Z., Lin, J., & Chen, J. (2011). IgM multiple myeloma presenting with bleeding tendency: a case report with immunophenotype analysis. Oncology letters, 2(1), 55-57. https://doi.org/10.3892/ol.2010.216
Zheng, Ling, et al. "IgM multiple myeloma presenting with bleeding tendency: a case report with immunophenotype analysis." Oncology letters vol. 2,1 (2011): 55-57. doi: https://doi.org/10.3892/ol.2010.216
Zheng L, Zeng Z, Lin J, Chen J. IgM multiple myeloma presenting with bleeding tendency: a case report with immunophenotype analysis. Oncol Lett. 2011 Jan;2(1):55-57. doi: 10.3892/ol.2010.216. Epub 2010 Nov 23. PMID: 22870128; PMCID: PMC3412457.
Copy Download .nbib Format: NLM
Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders.

International journal of molecular sciences

Mihályová J, Hradská K, Jelínek T, Motais B, Celichowski P, Hájek R.
PMID: 34768899
Int J Mol Sci. 2021 Oct 25;22(21). doi: 10.3390/ijms222111470.

Over the last few years, treatment principles have been changed towards more targeted therapy for many B-cell lymphoma subtypes and in chronic lymphocytic leukemia (CLL). Immunotherapeutic modalities, namely monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and chimeric...

Cite
Mihályová J, Hradská K, Jelínek T, et al. Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. Int J Mol Sci. 2021;22(21)doi: 10.3390/ijms222111470.
Mihályová, J., Hradská, K., Jelínek, T., Motais, B., Celichowski, P., & Hájek, R. (2021). Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. International journal of molecular sciences, 22(21), . https://doi.org/10.3390/ijms222111470
Mihályová, Jana, et al. "Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders." International journal of molecular sciences vol. 22,21 (2021). doi: https://doi.org/10.3390/ijms222111470
Mihályová J, Hradská K, Jelínek T, Motais B, Celichowski P, Hájek R. Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. Int J Mol Sci. 2021 Oct 25;22(21). doi: 10.3390/ijms222111470. PMID: 34768899; PMCID: PMC8584080.
Copy Download .nbib Format: NLM
Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation.

Sultan Qaboos University medical journal

Boulassel MR, Galal A.
PMID: 23269948
Sultan Qaboos Univ Med J. 2012 Aug;12(3):273-85. doi: 10.12816/0003140. Epub 2012 Jul 15.

Immunotherapy with T cells expressing chimeric antigen receptors (CAR) is being evaluated as a potential treatment for B-cell neoplasms. In recent clinical trials it has shown promising results. As the number of potential candidate antigens expands, the choice of...

Cite
Boulassel MR, Galal A. Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation. Sultan Qaboos Univ Med J. 2012;12(3):273-85doi: 10.12816/0003140.
Boulassel, M. R., & Galal, A. (2012). Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation. Sultan Qaboos University medical journal, 12(3), 273-85. https://doi.org/10.12816/0003140
Boulassel, Mohamed-Rachid, and Galal, Ahmed. "Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation." Sultan Qaboos University medical journal vol. 12,3 (2012): 273-85. doi: https://doi.org/10.12816/0003140
Boulassel MR, Galal A. Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation. Sultan Qaboos Univ Med J. 2012 Aug;12(3):273-85. doi: 10.12816/0003140. Epub 2012 Jul 15. PMID: 23269948; PMCID: PMC3529661.
Copy Download .nbib Format: NLM
mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting.

Oncoimmunology

Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ.
PMID: 29296519
Oncoimmunology. 2017 Oct 26;7(1):e1368604. doi: 10.1080/2162402X.2017.1368604. eCollection 2017.

Chimeric antigen receptor T cells (CAR-Ts) are promising cancer therapeutics. However, since cancer cells can lose the CAR-targeted antigen and avoid destruction, targeting multiple antigens with multiple CARs has been proposed. We illustrate here a less cumbersome alternative, anti-tag...

Cite
Lohmueller JJ, Ham JD, Kvorjak M, et al. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology. 2017;7(1):e1368604doi: 10.1080/2162402X.2017.1368604.
Lohmueller, J. J., Ham, J. D., Kvorjak, M., & Finn, O. J. (2017). mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology, 7(1), e1368604. https://doi.org/10.1080/2162402X.2017.1368604
Lohmueller, Jason J, et al. "mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting." Oncoimmunology vol. 7,1 (2017): e1368604. doi: https://doi.org/10.1080/2162402X.2017.1368604
Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology. 2017 Oct 26;7(1):e1368604. doi: 10.1080/2162402X.2017.1368604. eCollection 2017. PMID: 29296519; PMCID: PMC5739565.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries